key: cord-0723550-tqgmikn0
authors: Cui, Yuqing; Sun, Yali; Sun, Junyi; Liang, Huoyan; Ding, Xianfei; Sun, Xueyi; Wang, Dong; Sun, Tongwen
title: Efficacy and Safety of Corticosteroid Use in Coronavirus Disease 2019 (COVID-19): A Systematic Review and Meta-Analysis
date: 2021-08-13
journal: Infect Dis Ther
DOI: 10.1007/s40121-021-00518-3
sha: 070ebfd07f50faf3de8b5c410cc7c88fab10396e
doc_id: 723550
cord_uid: tqgmikn0

INTRODUCTION: We conducted a comprehensive literature review to synthesize evidence for the relationship between corticosteroid use and mortality in patients with COVID-19. METHODS: The PUBMED, EMBASE, and Cochrane Library were searched from inception to March 13, 2021. We searched and analyzed randomized controlled trials (RCTs) and observational studies (OSs) that examined corticosteroid use in patients with COVID-19. The primary outcome was in-hospital mortality, while the secondary outcome was the need for mechanical ventilation (MV) and serious adverse events. RESULTS: A total of 11 RCTs and 44 OSs involving 7893 and 41,164 patients with COVID-19 were included in the study. Corticosteroid use was associated with lower COVID-19 mortality in RCTs, but was not statistically significant (OR 0.91, 95% CI 0.77–1.07; I(2) = 63.4%). The subgroup analysis of pulse dose corticosteroid showed survival benefit statistically (OR 0.29, 95% CI 0.15–0.56). Moreover, the corticosteroid use may reduce the need for MV (OR 0.67, 95% CI 0.51–0.90; I(2) = 7.5%) with no significant increase in serious adverse reactions (OR 0.84, 95% CI 0.30–2.37; I(2) = 33.3%). In addition, the included OSs showed that the pulse dose (OR 0.66, 95% CI 0.45–0.95; I(2) = 30.8%) might lower the mortality in patients with COVID-19. The pulse dose of methylprednisolone (OR 0.60, 95% CI 0.45–0.80; I(2) = 0%) had a beneficial effect on survival. It was especially significant when the duration of pulse methylprednisolone use was less than 7 days (OR 0.59, 95% CI 0.43–0.80; I(2) = 0%). CONCLUSIONS: This meta-analysis indicated that corticosteroid use might cause a slight reduction in COVID-19 mortality. However, it could significantly reduce the MV requirement in patients with COVID-19 and restrict serious adverse events. Additionally, the pulse dose of methylprednisolone for less than 7 days may be a good treatment choice for patients with COVID-19. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40121-021-00518-3.

The rapid worldwide spread of coronavirus infections disease 2019 , caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has threatened global health seriously [1] . The virus causing COVID-19 is a novel betacoronavirus with 96% similarity to the bat coronavirus genome [2] . It is the third most highly transmissible and pathogenic coronavirus after the severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV) that appeared in the twenty-first century [3, 4] . Statistically, there have been 133,552,774 confirmed infections and 2,894,295 deaths worldwide by April 10, 2021 (https://www.who.int/data#reports).

There are some drugs, such as low molecular weight heparin, remdesivir, and convalescent plasma, that attracted people's attention during the COVID-19 epidemic. However, the results of recent large-scale, high-quality randomized controlled trials (RCTs) showed that there is no significant difference in the efficacy of convalescent plasma or remdesivir treatment between the control group and patients with COVID-19 [5, 6] . Corticosteroid administration is an important adjuvant treatment for severe viral infections because of its powerful anti-inflammatory effects [7] . During the SARS epidemic, corticosteroids were widely used in critically ill patients [8, 9] . Corticosteroid therapy is a rational option for patients with COVID-19 because it was previously used to treat patients with severe SARS [10] . Many COVID-19 RCTs have been registered to research the effect of corticosteroids on patients with COVID-19. Three recently published RCTs [11] [12] [13] demonstrated that corticosteroid use does not lower COVID-19 mortality; however, dexamethasone administration does have short-term survival benefits for patients with COVID-19 requiring respiratory support [14] . A prospective metaanalysis published in JAMA showed that corticosteroid use could reduce short-term all-cause mortality [15] . Corticosteroid treatment probably reduced mortality in patients with COVID-19 and non-COVID-19 acute respiratory distress syndrome (ARDS) [16] . The World Health Organization (WHO) also strongly recommended corticosteroid therapy in critically ill patients with COVID-19 recently (https://www. who.int/publications/i/item/WHO-2019-nCoVclinical-2021-1).

Despite there being several recent metaanalyses, the optimal corticosteroid type, dose, and duration in patients with COVID-19 remains unclear. This meta-analysis reviewed the RCT and OS literature comprehensively to establish a relationship between corticosteroid use and COVID-19 mortality. It aimed to explore the beneficial effect of corticosteroids, particularly in pulse methylprednisolone use in patients with COVID-19.

The meta-analysis (CRD42021242739) followed the PRISMA reporting guidelines [17] Table S2 gives the retrieval strategy in detail. EndNote X9 software was used to perform the literature screening process. Furthermore, we also looked up available references and searched the medRxiv website (https://www.medrxiv.org/) for relevant unpublished articles. The authors Yuqing Cui and Yali Sun searched the literature independently. This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.

The studies were included in the meta-analysis based on the following population, intervention, comparison, outcome, and study design (PICOS) criteria: (1) 

Available data were independently extracted on the basis of the afore mentioned eligibility criteria. The primary outcomes were the risk odds ratios (ORs) of mortality, and the secondary outcomes were the need for MV and safety of patients with COVID-19, with or without corticosteroid use. The data of each study were listed as follows: the study including first author and publication year, country, study design, gender, age, period of inclusion, sample size, corticosteroid type, daily dose and duration, disease severity, number of corticosteroid and non-corticosteroid use (deaths), follow-up, and the data of primary and secondary outcome. If ORs were missing, they were computed on the basis of original numerical values provided in the literature.

Cochrane Collaboration bias risk evaluation tool [18] and Newcastle-Ottawa scale (NOS) [19] were used to assess the bias risk of outcomes in RCTs and OSs, respectively. The selection bias, performance bias, detection bias, attrition bias, reporting bias, and other biases were used to assess the risk of an RCT. If any of these items were assessed as high risk, the study was considered to have a high risk of bias. Additionally, according to the OS selection (four points at most), the comparability of OS design and analysis (two points at most), and the adequacy of outcome measures (three points at most), a maximum of nine points could be awarded; seven to nine points were considered as high quality. The Grading of Recommendations, Assessment, Development and Evaluation (GRADE) criteria were used to estimate and summarize the quality of the RCT evidence and grade the collected data on the basis of evidence [20] .

Statistical analyses were conducted with STATA 14.0 (College Station, Texas, 77845, USA, Serial number 401406267051) and Review Manager (RevMan), version 5.3 (Cochrane Collaboration). Inverse variance random-effects meta-analyses were used for the included studies, and the pooled effect of each outcome was measured. The OR and 95% CI from each included study were either calculated or directly extracted from the data. I 2 estimated the heterogeneity of the included studies, where heterogeneity, not sampling error, resulted in variability. The heterogeneity was recorded as moderate when I 2 equaled 51-74% and was recorded as high when I 2 was more than 74%. Subgroup analyses were conducted on the basis of corticosteroid type and its dose and severity in patients with COVID-19. The stability of outcomes was verified by sensitivity analysis.

Funnel plots and Begg's linear regression were performed to evaluate the publication bias.

In total, we identified 6717 articles from the three databases. Three RCT records [DEXA-COVID 19 (The efficacy of dexamethasone treatment for patients with ARDS caused by COVID-19; NCT04325061); COVID STEROID (The hydrocortisone for COVID-19 and severe hypoxia; NCT04348305); Steroids-SARI (Glucocorticoid therapy for COVID-19 critically ill patients with severe acute respiratory failure; NCT04244591)] were searched by related metaanalysis [15] to obtain the prospective data; the other two unpublished records [21, 22] were identified by searching the medRxiv website. There were 4508 records left after removing the duplicates. Furthermore, we identified 106 studies after a preliminary screening by title or abstract. Finally, our meta-analysis included 11 RCTs and 44 OSs enrolling 7893 and 41,164 patients ( Fig. 1 ).

There 

Supplementary Material Fig. S1 presents the RCTs of the Cochrane Collaboration bias risk evaluation tool. Four RCTs [12, 14, 23, 26] were at high risk of bias because of performance bias. Three RCTs [11, 13, 25] were at low risk of bias, and one trial [24] had unclear risk bias. According to the NOS, all 44 eligible OSs [21, 22, scored greater than or equal to seven points, indicating a low risk of bias. Supplementary Material Table S4 reports the specific contents of risk bias in the included OSs. . 4) , particularly in patients with a duration less than 7 days (pulse methylprednisolone less than 7 days: OR 0.59, 95% CI 0.43-0.80; more than 7 days: OR 1.08, 95% CI 0.27-4.40) (Fig. 5) .

As a result of the high heterogeneity of our results, we conducted a sensitivity analysis to evaluate the impact of any single study on the pooled OR and 95% CI by omitting one study at a time. We found that the results of these RCTs and OSs were robust and reliable (Supplementary Material Figs. S5 A and B) .

We generated funnel plots (Supplementary Material Figs. S6 A and B) and performed Begg's regression tests to examine the publication bias of the included studies. There was no significant publication bias in RCTs (P = 0.732) and OSs (P = 0.659).

The meta-analysis identified 11 RCTs (7893 patients) and 44 OSs (41,164 patients) based on corticosteroid and COVID-19. The results of RCTs demonstrated that corticosteroid use had survival benefits, especially the pulse corticosteroid use. Furthermore, its use lowered the need for MV without significantly increasing the serious adverse events. Additionally, the OS analysis showed that the pulse dose of methylprednisolone for less than 7 days leads to a significant decrease in mortality. The pathophysiology of COVID-19 includes host-mediated excessive inflammation and cytokine storm that causes severe endothelial and alveolar damage [69] . COVID-19-related death is mainly due to excessive inflammation and uncontrolled immune response [70] .

Corticosteroids are well tolerated and widely used worldwide. They could reduce cytokine storm risk and inflammation in COVID-19 [71] . Moreover, they also could regulate inflammation-mediated lung injury, thereby reducing the progression of respiratory failure and death [14, 72] . Earlier studies on the efficacy and safety of corticosteroid therapy in severe pneumonia [73] indicated a significant association between corticosteroid use and reduction in ARDS risk as well as hospital and ICU length of stay [74] . Three recent high-quality meta-analyses [15, 75, 76] included RCTs and have shown a significant mortality advantage in corticosteroid-treated patients with COVID-19, in Fig. 2 Forest plot showing the association between corticosteroid dose and COVID-19 mortality in RCTs using the random-effects model. Low, using low dose of corticosteroid; high, using high dose of corticosteroid; pulse, using pulse dose of corticosteroid; using a fixed dose or b shock-dependent dose of corticosteroid Fig. 3 Forest plot showing the association between corticosteroid dose and COVID-19 mortality in OSs using the random-effects model. Low, using low dose of corticosteroid; high, using high dose of corticosteroid; pulse, using pulse dose of corticosteroid; Me, methylprednisolone; De, dexamethasone; early, early use of corticosteroid; delay, delayed use of corticosteroid; severe, using corticosteroid in severe cases; critical, using corticosteroid in critical cases; out-of-week-2-MP, receiving pulse dose of methylprednisolone at week 1 or 3; week-2-MP, receiving pulse dose of methylprednisolone during week 2; nonpulse, receiving non-pulse dose of methylprednisolone. a Receiving steroids within 48 h of ICU admission; b receiving steroids between 48 h and 7 days from admission; c receiving their first dose of steroids more than 7 days after ICU admission particular severely ill patients with COVID-19. The latest guidelines strongly recommend the short application of systemic corticosteroids in patients with MV, no matter whether complicated with ARDS or not [77] . Corticosteroids alter inflammatory pathways at the genomic level or through rapid non-genomic pathways [78] . The genomic mechanism includes activation of cytosolic glucocorticoid receptors, thereby activating or inhibiting protein synthesis, including cytokines, chemokines, and adhesion molecules, which has a direct inhibitory effect on inflammatory cells [79] . Non-genomic mechanisms may play other roles in pulse therapy [80] . At present, the existing evidence supports the use of corticosteroid in patients with COVID-19, but the type, dosage, starting time, and duration need more research.

Compared with dexamethasone, methylprednisolone had short half-life and high affinity for glucocorticoid receptor [81] . Pulse methylprednisolone use could quickly reach glucocorticoid receptor saturation to perform genomic and non-genomic functions [82] . Additionally, short-term corticosteroid treatment could minimize severe adverse effects, such as reduced excessive inflammation and exposure time, which may have obvious therapeutic effects.

This meta-analysis had several advantages. The study included the largest number of published RCTs and OSs, including manually searched meta-analysis and unpublished literature, available to date. Therefore, our study had the most comprehensive inclusion of articles. The GRADE and NOS were performed to assess the evidence quality and bias risk. The sensitivity analysis validated the study results to be robust and reliable. The starting time of corticosteroid administration is inconsistent in included studies, and there are few further studies on the dosage and duration of corticosteroid use. In our meta-analysis, we used as comprehensive literature as possible to explore suitable corticosteroids types, dosage, and duration in patients with COVID-19.

The study had a few limitations. Only one RCT on pulse dose, even though we searched all relevant literature; however, eight OSs were included and also confirmed the protective effect of pulse dose corticosteroid in patients with COVID-19. Our result was limited by high heterogeneity, which may come from differences in the study population, medical conditions, disease severity, type of corticosteroid used, dose, duration, and so on. It suggested that patients with COVID-19 with individual differences and different genotypes may need different glucocorticoid treatment strategies, such as different dosage or duration of use, but further larger-sample clinical trials are needed to explore this. However, the GRADE assessment showed our conclusions to be convincing.

The meta-analysis indicated that corticosteroid administration might be safe for COVID-19 treatments and showed a statistically significant difference in reducing the need for MV. Moreover, pulse methylprednisolone administration might have a beneficial effect on the survival of Compliance with Ethics Guidelines. This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.

Author Contributions. All the authors contributed substantially to the work presented in this article. TWS conceived of the study. YQC, YLS and JYS contributed to the data interpretation. HYL, XFD, XYS and DW contributed to the study protocol. TWS revised the article. All authors have approved the final and submitted version of the manuscript.

Data Availability. The datasets used and/or analysed in the present study are available from the corresponding author on reasonable request.

Disclosures. Yuqing Cui, Yali Sun, Junyi Sun, Huoyan Liang, Xianfei Ding, Xueyi Sun, Dong Wang and Tongwen Sun have nothing to disclose.

Authorship. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published. Open Access. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/bync/4.0/.

Early transmission dynamics in Wuhan, China, of novel coronavirusinfected pneumonia

Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan

Characteristics of SARS-CoV-2 and COVID-19

A comparative overview of COVID-19, MERS and SARS: review article

A randomized trial of convalescent plasma in Covid-Infect Dis Ther 19 severe pneumonia

Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial

Corticosteroids in severe pneumonia

Development of a standard treatment protocol for severe acute respiratory syndrome

Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience

A guide to COVID-19: a global pandemic caused by the novel coronavirus SARS-CoV-2

Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial

Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial

Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomized clinical trial

Dexamethasone in hospitalized patients with Covid-19

Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis

Corticosteroids in COVID-19 and non-COVID-19 ARDS: a systematic review and meta-analysis

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Methodological shortcomings predicted lower harm estimates in one of two sets of studies of clinical interventions

Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses

Grading quality of evidence and strength of recommendations in clinical practice guidelines. Part 1 of 3. An overview of the GRADE approach and grading quality of evidence about interventions

Corticosteroids are associated with increased survival in elderly presenting severe SARS-Cov2 infection

Corticosteroid use in severely hypoxemic COVID-19 patients: an observational cohort analysis of dosing patterns and outcomes in the early phase of the pandemic

Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial

No clinical benefit of high dose corticosteroid administration in patients with COVID-19: a preliminary report of a randomized clinical trial

Methylprednisolone as adjunctive therapy for patients hospitalized with COVID-19 (metcovid): a randomised, double-blind, phase IIb, placebo-controlled trial

Early use of corticosteroid may prolong SARS-CoV-2 shedding in non-intensive care unit patients with COVID-19 pneumonia: a multicenter, single-blind, randomized control trial

Corticosteroid treatment has no effect on hospital mortality in COVID-19 patients

Safety and efficacy of low-dose corticosteroids in patients with non-severe coronavirus disease 2019: a retrospective cohort study

Timing of corticosteroids impacts mortality in hospitalized COVID-19 patients

Efficacy of corticosteroid treatment for hospitalized patients with severe COVID-19: a multicentre study

Clinical features and short-term outcomes of 102 patients with coronavirus disease 2019 in Wuhan, China

Corticosteroid therapy is associated with improved outcome in critically ill patients with COVID-19 with hyperinflammatory phenotype

Corticosteroid pulses for hospitalized patients with COVID-19: effects on mortality

A retrospective controlled cohort study of the impact of glucocorticoid treatment in SARS-CoV-2 infection mortality

Clinical profile, treatment and predictors during the first COVID-19 wave: a population-based registry analysis from Castile and Leon Hospitals

Dexamethasone use and mortality in hospitalized patients with coronavirus disease 2019: a multicentre retrospective observational study

A real-world study of glucocorticoid treatment in COVID-19 patients with different disease severities

Effect of systemic glucocorticoids on mortality or mechanical ventilation in patients with COVID-19

A comparison of methylprednisolone and dexamethasone in intensive care patients with COVID-19

Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan

Adverse outcomes associated with corticosteroid use in critical COVID-19: a retrospective multicenter cohort study

Corticosteroid therapy in critically ill patients with COVID-19: a multicenter, retrospective study

Corticosteroids treatment of patients with coronavirus disease 2019: a propensity score matching study

Corticosteroid treatment in severe COVID-19 patients with acute respiratory distress syndrome

Low-to-moderate dose corticosteroids treatment in hospitalized adults with COVID-19

Adjuvant corticosteroid therapy for critically ill patients with COVID-19

Corticosteroid therapy for patients with severe novel coronavirus disease 2019

Efficacy of corticosteroids in non-intensive care unit patients with COVID-19 pneumonia from the New York Metropolitan region

Lack of detrimental effect of corticosteroids on antibody responses to SARS-CoV-2 and viral clearance in patients hospitalized with COVID-19

Corticosteroids in patients hospitalised for COVID-19 pneumonia who require oxygen: observational comparative study using routine care data

Early corticosteroids are associated with lower mortality in critically ill patients with COVID-19: a cohort study

Impact of late administration of corticosteroids in COVID-19 ARDS

Clinical outcomes associated with methylprednisolone in mechanically ventilated patients with COVID-19

High-dose methylprednisolone in nonintubated patients with severe COVID-19 pneumonia

Effectiveness of glucocorticoids in patients hospitalized for severe SARS-CoV-2 pneumonia

Impact of systemic corticosteroids on mortality in older adults with critical COVID-19 pneumonia

Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)

Second week methyl-prednisolone pulses improve prognosis in patients with severe coronavirus disease 2019 pneumonia: an observational comparative study using routine care data

Early experience with methylprednisolone on SARS-CoV-2 infection in the African American population, a retrospective analysis

Prolonged low-dose methylprednisolone in patients with severe COVID-19 pneumonia

Prevalence of diabetes, management and outcomes among Covid-19 adult patients admitted in a specialized tertiary hospital in Riyadh, Saudi Arabia

Impact of heart failure on the clinical course and outcomes of patients hospitalized for COVID-19. Results of the Cardio-COVID-Italy multicentre study

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China

Corticosteroid therapy for coronavirus disease 2019-related acute respiratory distress syndrome: a cohort study with propensity score analysis

Systemic corticosteroids and mortality in severe and critical COVID-19 patients in Wuhan

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Effect of methylprednisolone in severe and critical COVID-19: analysis of 102 cases

Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review

Attenuating the effects of novel COVID-19 (SARS-CoV-2) infection-induced cytokine storm and the implications

Cytokine storm in COVID-19-immunopathological mechanisms, clinical considerations, and therapeutic approaches: the REPROGRAM Consortium Position Paper

COVID-19 with different severities: a multicenter study of clinical features

Efficacy and safety of corticosteroids for Infect Dis Ther community-acquired pneumonia: a systematic review and meta-analysis

Efficacy and safety of corticosteroids in immunocompetent patients with septic shock

Corticosteroid use in COVID-19 patients: a systematic review and meta-analysis on clinical outcomes

Impact of corticosteroids in coronavirus disease 2019 outcomes: systematic review and metaanalysis

Surviving Sepsis Campaign guidelines on the management of adults with coronavirus disease 2019 (COVID-19) in the ICU: first update

Transitioning from basic toward systems pharmacodynamic models: lessons from corticosteroids

Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids

Non-genomic effects of glucocorticoids: an updated view

Evaluation of AP-1 and NF-kB inhibitory potency for oral glucocorticoids

Different glucocorticoids vary in their genomic and non-genomic mechanism of action in A549 cells

We would like to thank the Chinese Evidence Based Medicine Center, West China Hospital, Sichuan University, for providing the Stata 14.0 statistical software.